title: Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls.
abstract: Cholecystokinin (CCK), beta-endorphin (BE), and vasoactive intestinal peptide (VIP) in peripheral blood mononuclear cells from 30 drug-naive schizophrenics compared to 22 healthy controls were studied. Patients were evaluated with the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of the Negative Symptoms (SANS) at baseline (TO), and after four weeks (T4) in nine patients who were subsequently treated with haloperidol (HL). Neuropeptide concentrations in peripheral blood mononuclear cells (PBMC) were measured at TO and, for the treated patients, at T4. There was a negative correlation between CCK and SANS baseline scores and a trend for patients who responded poorly to HL (i.e. patients with a prevalence of negative symptomatology) to have lower CCK basal values.
authors.affiliation: Department of Clinical Psychiatry, University of Milan, I.R.C.C.S., Ospedale Maggiore di Milano, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Mauri
authors.forename: R
authors.initials: R
authors.lastname: Rudelli
authors.forename: S
authors.initials: S
authors.lastname: Vanni
authors.forename: G
authors.initials: G
authors.lastname: Panza
authors.forename: A
authors.initials: A
authors.lastname: Sicaro
authors.forename: D
authors.initials: D
authors.lastname: Audisio
authors.forename: P
authors.initials: P
authors.lastname: Sacerdote
authors.forename: A E
authors.initials: AE
authors.lastname: Panerai
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001526:Behavioral Symptoms / Q000145:classification; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D002766:Cholecystokinin / Q000097:blood / Q000187:drug effects; D005260:Female; D006220:Haloperidol / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000737:chemistry / Q000187:drug effects*; D008297:Male; D009479:Neuropeptides / Q000097:blood / Q000187:drug effects*; D012044:Regression Analysis; D012559:Schizophrenia / Q000097:blood / Q000145:classification / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014660:Vasoactive Intestinal Peptide / Q000097:blood / Q000187:drug effects; D001615:beta-Endorphin / Q000097:blood / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D009479:Neuropeptides; D014660:Vasoactive Intestinal Peptide; D001615:beta-Endorphin; D002766:Cholecystokinin; D006220:Haloperidol